News

Sanofi plans to axe 2000 jobs
Enlarge image

BusinessFrance

Sanofi plans to axe 2000 jobs

06.07.2012 - The French pharma giant is preparing for a major overhaul of activities in its home market.

Exact numbers are not yet final, but French unions already fear the worst. An estimate of 2,000 jobs lost is “probably close to reality,” said Thierry Bodin, a representative of the CGT union after a meeting with managers today. Europe’s third-biggest drugmaker wants to regroup its research in the Paris region and around Lyon, he said. This might be the end for research in Toulouse, where the blockbuster Plavix blood thinner was developed, and Montpellier. The company also plans to eliminate support functions and cut jobs at its Pasteur vaccine division, Bodin said.

Reuters reports, that Chief Executive Chris Viehbacher told employees that the unspecified number of job cuts, at its Toulouse and Montpellier sites, would be achieved through voluntary redundancies, early retirement and internal mobility. Manufacturing sites in France would not be affected by the project. Jean-Marc Podvin, a spokesman for Sanofi, said in a telephone interview with Bloomberg Businessweek, that no job cut figures were given and all options remain open for Toulouse. Montpellier could become a centre focused on clinical development, he added.

The company’s CEO Viehbacher began to restructure Sanofi in 2009 reducing headcount, closing plants and dropping the least promising projects. As part of a strategic shift, the French drugmaker is aiming at reducing internal research and having other actors, such as small biotechs, academic research to find new molecules and vaccines.

In its course to concentrate on its core competencies, Sanofi has decided to divest its 19.3% stake in the Yves Rocher Group, which operates in a variety of sectors, including cosmetics, home care products and clothing. The Rocher family which already controls most of the company will buy the shares and raise its stake to more than 95%.

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014